



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$34.65
Change (%)	▲ 0.71 (2.09%)
Volume	846,683
52 Week Low	\$24.47
Market Cap	\$1,390,672,358
Rolling EPS	1.03
PE Ratio	33.0326
Shares Outstanding	40,974,436

Data as of 06/23/17 4:07 p.m. ET



Recent Headlines & Events

05/11/17

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available

05/10/17

Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore

05/09/17

Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/26/17	4
05/26/17	4
05/26/17	4
05/26/17	4

Primary IR Contact

Robert G. Burrows
Vice President,
Investor Relations
Emergent BioSolutions Inc.
Phone: (240) 631 3280
Fax: (240) 413-1917
E-mail: burrowsr@ebsi.com

Data provided by Nasdaq. Minimum 15 minutes delayed.